← SynDRA
TAZAROTENE
SynDRA canonical compound SYN0016463 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | RARG |
| Mechanism of action | Retinoid receptor agonist |
| Indication | cosmetic | sunscreen lotion |
| Disease area | dermatology |
All known targets
Mechanisms of action (all sources)
- Retinoid receptor agonist
- RARG AGONIST
- Retinoic acid receptor agonist
- RARB AGONIST
- RARA AGONIST
- RARG BINDER
Drug classes
- Dermatologic Agents
- Keratolytic Agents
- Noxae
- Teratogens
- Retinoid
ATC classes
- D05A · ANTIPSORIATICS FOR TOPICAL USE
Cross-references
Synonyms
- tazorac
- fabior
- AGN-190168
- Tazaroteno
- Idp-123
- AGN190168
- Arazlo
- Avage
- Fabior
- Tazarotene component of duobrii
- Tazarotene component of idp-118
- Tazorac
- Zorac
- Suretin
- Tazarotenum
- Tazoral
- Avage (TN)
- Tazarotene [USAN:INN]
- Tazorac (TN)
- Zorac (TN)
- Tazarotene (JAN/USAN/INN)
- Tazorac, Avage, Zora, Tazarotene
- Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
- Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
- Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate
- Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
- 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester
- 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
- IDP-118 COMPONENT TAZAROTENE
- AGN 190168
- ARAZLO
- DUOBRII COMPONENT TAZAROTENE
- tazaroteno
- tazarotenum
- DTXCID3026691
- CHEBI:32184
- ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
- ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
Reported adverse events
- Sunburn
- Application site erythema
- Application site pain
- Application site pruritus
- Application site dryness
- Application site exfoliation
- Application site dermatitis
- Application site irritation
- Erythema
- Rash
- Cheilitis
- Dermatitis
Look up TAZAROTENE in the interactive SynDRA portal →